* Study Title:

Your ad should begin with a brief one or two sentence title, which is the first thing a patient will see before viewing the entire listing. This title should provide an overview of the study, including but not limited to, the following information:
- Study Phase
- Type of Study
- Illness/Indication targeted
- Type of Treatment
- If possible, one major inclusion/exclusion criteria

Click here to see where your study title will be posted.

Official Title:

* Condition:

Please refer to NLM Medical Subject Headings [MeSH] controlled vocabulary.

Study Phase:

Phase I
Phase II
Phase III
Phase IIIb/IV

Overall Recruiting Status:

	Not yet recruiting: participants are not yet being recruited or enrolled
	Recruiting: participants are currently being recruited and enrolled
	No longer recruiting: participants are no longer being recruited or enrolled
	Completed: participants are no longer being recruited; data analysis is complete
	Suspended: recruiting or enrolling participants has halted but potentially will resume
	Terminated: recruiting or enrolling participants has halted and will not resume

* Trial Listing Approval:

	Yes, the study listing is IRB approved. I do have documentation of this approval, and upon request, I agree to provide a copy of this documentation to Thomson CenterWatch.
	No, this study listing is not yet IRB approved
	No, the listing isn't IRB approved, but it does meet the FDA information sheet #29 guidelines for posting a trial online

Research Ethics Review:

Has the study at the time of registration received appropriate ethics committee approval?
Yes
No

If yes, enter ethics commitee name here

* Study Description:

The ad should be worded in a patient-friendly manner.

Click here to see where your study description will be posted.

* Patient Inclusion Criteria:

Click here to see where your study criteria will be posted.

* Patient Exclusion Criteria:

Click here to see where your study criteria will be posted.

Primary Outcomes

The specific measure that will be used to determine the effect of the intervention(s)

Key Secondary Outcomes

Other measures that will be used to evaluate the intervention(s).

Intervention Type:

Drug
Gene Transfer
Vaccine
Behavior
Device
Procedure

Intervention Name

Primary Sponsor / CRO:

Secondary Sponsor (if applicable)

Funding Source

Collaborators

Secondary IDs

Other identification numbers assigned to the protocol, including any applicable NIH grant numbers. Provide up to 5 secondary ID numbers. Example: NCI-793-0115D

Overall Study Officials

Person(s) responsible for overall scientific leadership of the protocol

Study Type

Interventional
Observational

Study Start Date:

Include Month and Year

Target Number of Subjects:

* Center Name:

Contact Name:

Title:

* Address:

* City:

* State:

* Zip code:

* Country:

* Phone:

Fax:

Email:

Although it is not required, you are especially encouraged to include an email address. With an email address on your trial posting, a template is automatically generated at the bottom of the trial with which a patient can post a confidential message to you.

Company Name:

* Contact Name:

Title:

Address:

* Phone:

Fax:

Email:

Company Name:

Contact Name:

Title:

Billing Address:

Phone:

Fax:

Email:

Yes

No

If so, please type PO Number here: